Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Investor Eye: Charities Could Be The Best Option For Start-ups

Executive Summary

One of the UK’s largest charities, Macmillan, has launched a fund to invest in start-ups that aim to benefit the lives of cancer patients.

You may also be interested in...



AstraZeneca And Huma On Digital’s Value For Pharma

Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.

Podcast: OxSonics Hopes To Use Ultrasound To Enhance Drug Efficacy – Without Reformulation

In this one-off podcast, reporter Barnaby Pickering speaks Jérôme Marzinski and Dr Christian Coviello, the CEO and CTO, respectively, of OxSonics, a UK-based start-up which is working on an ultrasound-based technology that has been designed to enhance the potency of oncological drugs.

Speaking To AstraZeneca And Huma About Digital’s Value For Pharma

AstraZeneca has been working with Huma to develop a series of software-based tools for monitoring patients. Medtech Insight spoke to both companies about the value of these partnerships and the potential challenges.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel